SI1573335T1 - Cvd test - Google Patents

Cvd test

Info

Publication number
SI1573335T1
SI1573335T1 SI200331123T SI200331123T SI1573335T1 SI 1573335 T1 SI1573335 T1 SI 1573335T1 SI 200331123 T SI200331123 T SI 200331123T SI 200331123 T SI200331123 T SI 200331123T SI 1573335 T1 SI1573335 T1 SI 1573335T1
Authority
SI
Slovenia
Prior art keywords
calprotectin
antibody
assay
cvd
body fluid
Prior art date
Application number
SI200331123T
Other languages
English (en)
Inventor
Erling Axis-Shield Sundrehagen
Original Assignee
Axis Shield Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axis Shield Asa filed Critical Axis Shield Asa
Publication of SI1573335T1 publication Critical patent/SI1573335T1/sl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Gyroscopes (AREA)
  • Optical Head (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analyzing Materials By The Use Of Ultrasonic Waves (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200331123T 2002-12-20 2003-12-22 Cvd test SI1573335T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0229747.1A GB0229747D0 (en) 2002-12-20 2002-12-20 Assay
EP03786143A EP1573335B1 (en) 2002-12-20 2003-12-22 Cvd assay
PCT/GB2003/005607 WO2004057341A2 (en) 2002-12-20 2003-12-22 Cvd assay

Publications (1)

Publication Number Publication Date
SI1573335T1 true SI1573335T1 (sl) 2008-04-30

Family

ID=9950111

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331123T SI1573335T1 (sl) 2002-12-20 2003-12-22 Cvd test

Country Status (16)

Country Link
US (3) US10101325B2 (sl)
EP (2) EP1573335B1 (sl)
JP (2) JP4653492B2 (sl)
CN (3) CN1729398B (sl)
AT (2) ATE380345T1 (sl)
AU (1) AU2003295142A1 (sl)
CA (2) CA2729365C (sl)
DE (2) DE60327007D1 (sl)
DK (2) DK1739430T3 (sl)
ES (2) ES2297250T3 (sl)
GB (1) GB0229747D0 (sl)
NO (1) NO20052161L (sl)
PL (2) PL216385B1 (sl)
PT (1) PT1573335E (sl)
SI (1) SI1573335T1 (sl)
WO (1) WO2004057341A2 (sl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0229747D0 (en) * 2002-12-20 2003-01-29 Axis Shield Asa Assay
US7501256B2 (en) 2004-07-23 2009-03-10 Aspenbio Pharma, Inc. Methods and devices for diagnosis of appendicitis
US7659087B2 (en) 2004-07-23 2010-02-09 Aspenbio Pharma, Inc. Methods and devices for diagnosis of appendicitis
EP1862805A1 (en) * 2006-06-01 2007-12-05 University of Zürich The use of mrp 8/14 levels for discrimination of individuals at risk of acute coronary syndromes
EP2403624A4 (en) * 2009-03-02 2012-08-22 Dignity Health DIAGNOSTIC DEVICES AND METHODS OF USE
PL2427482T3 (pl) * 2009-05-07 2020-08-24 Chreto Aps Sposób oczyszczania docelowych polipeptydów
US9574977B2 (en) * 2013-02-26 2017-02-21 Innova Prep Liquid to liquid biological particle concentrator with disposable fluid path
EP2511704A1 (en) 2011-04-13 2012-10-17 Immundiagnostik AG Assay method for intrinsic acute kidney injury
NO20110895A1 (no) * 2011-06-21 2012-12-24 Magne Fagerhol Kompetitive S100A9 immunoanalyser
ES2402457B2 (es) * 2011-10-19 2014-01-20 Universidade De Vigo Procedimiento para el diagnóstico de derrame pleural maligno mediante la determinación de la concentración de calprotectina en líquido pleural.
US9122968B2 (en) 2012-04-03 2015-09-01 X-Card Holdings, Llc Information carrying card comprising a cross-linked polymer composition, and method of making the same
US9439334B2 (en) 2012-04-03 2016-09-06 X-Card Holdings, Llc Information carrying card comprising crosslinked polymer composition, and method of making the same
KR20150043566A (ko) * 2012-09-12 2015-04-22 버그 엘엘씨 심장독성 약제의 동정에 마커를 사용하는 용도
US10906287B2 (en) 2013-03-15 2021-02-02 X-Card Holdings, Llc Methods of making a core layer for an information carrying card, and resulting products
ES2948232T3 (es) * 2017-02-07 2023-09-06 Lyfstone B V Biomarcadores para diagnosticar el riesgo de revisión del implante relacionado con el implante debido a un aflojamiento aséptico
EP3385712A1 (en) 2017-04-03 2018-10-10 Gentian AS Improved calprotectin assay
EP3622293A1 (en) 2017-05-09 2020-03-18 Immundiagnostik AG Method for determination of members of the s100 family of calcium binding proteins by immunoturbidimetry
CN108196066A (zh) * 2018-01-22 2018-06-22 安徽伊普诺康生物技术股份有限公司 一种测定钙防卫蛋白的试剂盒及其制备使用方法
EP3762871B1 (en) 2018-03-07 2024-08-07 X-Card Holdings, LLC Metal card
US20230184787A1 (en) * 2020-05-13 2023-06-15 Nordic Bioscience A/S Calprotectin Assay

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287202A (en) 1978-05-26 1981-09-01 Horrobin David F Treatment and/or prophylaxis of spasms of coronary arteries
JPS55162059A (en) * 1979-06-05 1980-12-17 Mochida Pharmaceut Co Ltd Measuring method for antigen, antibody or their complex and measurement reagent kit
US4401765A (en) * 1981-09-01 1983-08-30 E. I. Du Pont De Nemours And Company Covalently bonded high refractive index particle reagents and their use in light scattering immunoassays
US4480042A (en) * 1981-10-28 1984-10-30 E. I. Du Pont De Nemours And Company Covalently bonded high refractive index particle reagents and their use in light scattering immunoassays
GB8318754D0 (en) 1983-07-11 1983-08-10 Fagerhol M K F Human proteins anti-sera test kits
JPS60139621A (ja) 1983-12-27 1985-07-24 Grelan Pharmaceut Co Ltd 抗血栓剤
JPS625970A (ja) 1985-03-15 1987-01-12 Terumo Corp ピラジン誘導体およびこれを含有する血小板凝集抑制剤
EP0310361A3 (en) * 1987-09-30 1989-05-24 Beckman Instruments, Inc. Tridentate conjugate and method of use thereof
GB2218100A (en) 1988-03-02 1989-11-08 Erling Sundrehagen Conjugates for the detection and/or quantification of antigenic substances in body fluids
CA2023803C (en) * 1989-08-23 1999-05-18 Takeshi Miyazaki Method for measuring an immunologically active material and apparatus suitable for practicing said method
US5455160A (en) * 1993-05-27 1995-10-03 Fagerhol; Magne K. Diagnostic test and kit for disease or disorders in the digestive system
US5776348A (en) 1995-02-07 1998-07-07 Massachusetts Institute Of Technology Mineral precipitation system and method for inhibiting mineral precipitate formation
ATE278964T1 (de) 1996-11-01 2004-10-15 Magne K Fagerhol Verfahren zur proteinextraktion
PT1003501E (pt) 1997-04-02 2005-07-29 Brigham & Womens Hospital Utilizacao de um agente para reduzir o risco de doencas cardiovasculares
GB9816088D0 (en) 1998-07-23 1998-09-23 Axis Biochemicals Asa System
WO2000011479A1 (en) * 1998-08-20 2000-03-02 Axis-Shield Asa Assay method for cardiovascular disease
ES2358576T3 (es) * 1999-07-05 2011-05-11 K.U. LEUVEN RESEARCH & DEVELOPMENT Detección de la actividad del factor de von-willebrand (vwf).
AU782386C (en) 1999-08-31 2006-08-10 Brigham And Women's Hospital Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
FR2800636A1 (fr) * 1999-11-05 2001-05-11 Bio Merieux Particules composites, conjugues derives, leur procede de preparation et utilisations
US7011952B2 (en) * 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US20030059461A1 (en) * 2000-06-06 2003-03-27 Sibtech, Inc. Molecular delivery vehicle for delivery of selected compounds to targets
WO2002018953A1 (fr) * 2000-08-29 2002-03-07 Kyowa Medex Co.,Ltd Reactifs et methode d'immunoessai d'agglutination fortement reproductible
JP2002318233A (ja) * 2001-04-19 2002-10-31 Shino Test Corp 測定対象物質の比濁法測定試薬及び測定対象物質の比濁法測定方法
EP1666881B1 (en) * 2001-05-04 2010-02-17 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
GB0229747D0 (en) * 2002-12-20 2003-01-29 Axis Shield Asa Assay
FR2872579B1 (fr) * 2004-06-30 2006-11-24 Pasteur Institut Detection de la tuberculose et de l'infection par mycobacterium tuberculosis a l'aide de hbha
US7623910B2 (en) * 2006-03-10 2009-11-24 University Of Rochester ECG-based differentiation of LQT1 and LQT2 mutation

Also Published As

Publication number Publication date
CA2729365A1 (en) 2004-07-08
DK1739430T3 (da) 2009-07-13
ES2323475T3 (es) 2009-07-16
JP2010019849A (ja) 2010-01-28
ATE427498T1 (de) 2009-04-15
US20060134705A1 (en) 2006-06-22
EP1739430B1 (en) 2009-04-01
GB0229747D0 (en) 2003-01-29
CN1729398B (zh) 2012-04-04
CN101893635A (zh) 2010-11-24
DE60317931T2 (de) 2008-11-13
EP1573335A2 (en) 2005-09-14
AU2003295142A1 (en) 2004-07-14
CN101893635B (zh) 2014-04-09
ES2297250T3 (es) 2008-05-01
JP5744385B2 (ja) 2015-07-08
JP4653492B2 (ja) 2011-03-16
ATE380345T1 (de) 2007-12-15
CN102608326A (zh) 2012-07-25
CA2729365C (en) 2018-09-18
EP1739430A2 (en) 2007-01-03
WO2004057341A3 (en) 2004-10-21
PT1573335E (pt) 2007-12-21
US20110318847A1 (en) 2011-12-29
US20190049439A1 (en) 2019-02-14
DE60317931D1 (en) 2008-01-17
DK1573335T3 (da) 2008-04-14
EP1573335B1 (en) 2007-12-05
WO2004057341A2 (en) 2004-07-08
EP1739430A3 (en) 2007-01-17
DE60327007D1 (de) 2009-05-14
PL216385B1 (pl) 2014-03-31
NO20052161L (no) 2005-07-19
CA2504876A1 (en) 2004-07-08
JP2006510895A (ja) 2006-03-30
US10101325B2 (en) 2018-10-16
PL377476A1 (pl) 2006-02-06
PL394295A1 (pl) 2011-09-12
NO20052161D0 (no) 2005-05-03
CN1729398A (zh) 2006-02-01

Similar Documents

Publication Publication Date Title
NO20052161L (no) Analysemetode for hjerte-karsykdom
Sener et al. Rapid real-time detection of procalcitonin using a microcontact imprinted surface plasmon resonance biosensor
EP2538218A3 (en) Biochemical markers for CVD risk assessment
DE60219207D1 (de) Diagnostisches testverfahren
MY162697A (en) Methods, devices and kits for detecting or monitoring acute kidney injury
WO2009117510A3 (en) Multi-wavelength analyses of sol-particle specific binding assays
WO2010038974A3 (ko) 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트
ATE410684T1 (de) Molekular-modifikations-assays
NZ592552A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
DE602007012248D1 (de) Nanosensoren und entsprechende technologien
JP2012509477A5 (sl)
WO2006047591A3 (en) Rapid microfluidic assay for analyte interactions
MX2009003572A (es) Metodos para reducir interferencia optica en un dispositivo de fluido.
WO2006119155A3 (en) Diagnostic serum antibody profiling
WO2005073405A3 (en) Catalytic polynucleotide and its use for determination of analytes
ATE467128T1 (de) Kolloidale metallkonjugate
IláKim Detection and quantification of the Bcr/Abl chimeric protein on biochips using LDI-TOF MS
CN103575875A (zh) 一种新的功能化金纳米棒免疫探针及金纳米棒生物芯片的制备方法及应用
JP2009544971A5 (sl)
WO2008067008A3 (en) A method for the quantitative evaluation of sex hormones in a serum sample
WO2006119262A3 (en) Detection of carbohydrate biomarkers
DE60332479D1 (de) Holo-transcobalamin bindungspartner und ihre verwendung in cobalamintest
WO2006044888A3 (en) Reagents for urine-based immunological assays
Li et al. Flow sandwich immunoassay for specific anti-OVA IgG antibody by use of surface plasmon resonance sensor
ATE520985T1 (de) Verfahren zur bestimmung von antigen und antikörper gegen das antigen